Metastatic pancreatic adenocarcinoma trang 1 tải miễn phí từ TAILIEUCHUNG

"Metastatic pancreatic adenocarcinoma" trang 1 - tải miễn phí từ Tailieuchung

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

8 52 1

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study

Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: A prospective cohort study

9 64 0

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study

Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: A retrospective study

9 99 0

PDAC-ANN: An artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression

PDAC-ANN: An artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression

11 53 0

Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma

Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma

20 9 1

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience

7 61 1

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

7 65 1

Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

11 55 1

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

11 55 1

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: A retrospective observational study

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: A retrospective observational study

9 30 1

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells

E-cadherin might be a stage-dependent modulator in aggressiveness in pancreatic cancer cells

8 30 1

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: Does sequence matter?

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: Does sequence matter?

8 60 1

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

7 53 0

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: A multicentric study

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: A multicentric study

12 47 1

A randomized phase II study of weekly nabpaclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: The AFUGEM GERCOR trial

A randomized phase II study of weekly nabpaclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: The AFUGEM GERCOR trial

11 44 1

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: A retrospective cohort study

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: A retrospective cohort study

9 41 1

Pancreatic adenocarcinoma: Insights into patterns of recurrence and disease behavior

Pancreatic adenocarcinoma: Insights into patterns of recurrence and disease behavior

8 49 0

Báo cáo y học: " A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma"

15 46 0

báo cáo khoa học:

báo cáo khoa học: "Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis"

10 45 0

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.